WeTrials
Recruiting

A Phase III Randomized Trial of Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab (Avastin) With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed Glioblastoma (GBM)

What is this study?

This study is testing a special way to deliver a medication called Bevacizumab directly to brain tumors using a targeted procedure, combined with standard radiation and chemotherapy. Researchers want to see if this method helps patients with a newly diagnosed aggressive brain cancer live longer without the cancer growing.

Who can participate?

Adults 18 and older who have been newly diagnosed with a specific type of aggressive brain cancer called glioblastoma may be able to join. Participants need to be well enough to perform daily activities and able to undergo regular MRI brain scans.

What will happen?

Participants will be randomly placed into one of two groups where one group receives the specialized drug delivery along with standard care, and the other receives standard care alone. The study team will closely monitor your health, side effects, and overall quality of life throughout the process.

Where and when?

This study is currently recruiting patients and takes place in New York, New York, United States.

Key Points
  • 1Tests a targeted delivery method for Bevacizumab directly to the brain.
  • 2Compares the new treatment approach against standard care for glioblastoma.
  • 3Currently actively recruiting participants in New York.

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
GlioblastomaGlioblastoma MultiformeGlioma, MalignantGBMBrain CancerGlioblastoma, IDH-wildtypeGlioblastoma Multiforme, Adult

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.